Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male Volunteers

Phase 1 Study to Determine the Pharmacodynamic and Safety of MEDITOXIN®(Clostridium Botulinum Toxin Type A) in Healthy Male Volunteers

This study will determine the pharmacodynamic and safety of MEDITOXIN® in healthy male volunteers.

Inclusion Criteria:

• Male adults aged between 20 and 45
• Satisfying baseline nerve conduction criteria in below at screening visit CMAP M-wave amplitude of EDB ≥ 4.0mV CMAP M-wave amplitude of AH ≥ 5.0mV CMAP M-wave amplitude of ADQ ≥ 5.0mV

Exclusion Criteria:

• Have history of childhood botulism
• Have a pacemaker or any other heart device
• Have peripheral neuropathy or accessary peroneal nerve
• Have history of lower limb myotomy or denervation surgery